Normal tissue homeostasis requires a finely balanced interaction between phagocytic scavenger cells (such as monocytes and macrophages) that degrade senescent material and mesenchymal cells (such as fibroblasts and smooth muscle cells
Introduction
Macrophages and monocytes are not only essential in the host response to various invasive stimuli, but also play an important role in normal tissue turnover, and aseptic wound healing and repair (1, 2) . An important element of these complex responses is the coordinated secretion of a variety of mitogenic factors and cytokines to act locally in both an autocrine and paracrine manner.
Recently, it has become apparent that growth factors and cytokines which are largely generated in response to exogenous stimuli are also elicited in response to the in vivo nonenzymatic modification of tissue components by glucose (3, 4) .
Advanced glycosylation end products (AGEs), ' the late rearrangement products ofthese glucose-protein reactions are irreversible cross-linking adducts which accumulate on proteins in vivo as a function of protein half-life, chronological age, and ambient glucose levels (5, 6) . Excessive accumulation of AGE adducts on aging and diabetic tissues is thought to lead to irreversible tissue damage, in part by widespread protein crosslinking and protein trapping (5) . A novel system of membrane-associated receptors, comprising at least a 90-and a 60-kD protein specific for the ingestion and elimination of proteins modified by AGEs has been identified on both murine peritoneal macrophages and human monocytes (7, 8) . In addition, the interaction of AGE-modified proteins with AGE receptors triggers the synthesis and release ofcytokines, in particular interleukin-I1, (IL-lI f) and tumor necrosis factor-a (TNFa) (3) . In that each of these AGE-induced mediators can promote growth responses in various cells, it was proposed that such responses may be central in normal tissue remodeling, in the delivering ofsignals to nearby mesenchymal cells to replace senescent tissue with new matrix and cellular components. This second limb of the dual-effector functions of the monocyte AGE-receptor system, i.e., the initiation of tissue repair processes, is further assisted by the AGE-induced secretion of platelet-derived growth factor (PDGF), a competence factor for mesenchymal cells (9) . The final stimulus for proliferation had not been identified, however.
It has been proposed that once cells, such as fibroblasts and smooth muscle cells, are rendered competent, proliferation can in turn be stimulated by progression-type growth factors such as insulin-like growth factor I (IGF-I) (9, 10) . IGF-I belongs to the somatomedin family ofpeptides, which are structurally homologous to proinsulin (10, 11), and interact with specific surface receptors on various target cells. Several different forms ofIGF-I have been identified. Mature liver IGF-I with an M, of 7.6 kD is secreted into the circulation (hence the plasma form of IGF-I), where it is associated with a binding protein complex of -150 kD (12) (13) (14) . Cultured smooth muscle cells, fibroblasts, and activated alveolar macrophages have all been shown to secrete IGF-I (15) (16) (17) , and these "tissue-type" somatomedin-like peptides have molecular masses approximately threefold greater (21-25 kD) than the plasma form of IGF-I. Macrophages, isolated from healing wound sites have been shown to produce IGF-I mRNA (1) . Thus, although activated tissue macrophages are recognized as capable of IGF-I synthesis, circulating monocytes have not been noted to do so.
The present studies reveal that IGF-I mRNA and prohormone are induced in human monocytes after stimulation by AGE-modified proteins, but not by lipopolysaccharide (LPS) or interferon-T (IFN-T). The induction of IGF-I is mediated via the monocyte AGE-receptor system and appears to depend on IL-IB and PDGF protein secretion. These data strongly support the notion that the natural formation of AGE-proteins in tissues may contribute to the regulation of tissue remodeling through the induction first of "inflammatory" cytokines, then of competence, and ultimately of progression factors, all of which may cooperate closely to coordinate the removal and replacement of molecular and cellular tissue components.
Methods
Cellpreparations, treatments, and RNA extraction. Human peripheral blood monocytes were isolated from fresh blood of healthy volunteers using Ficoll-Hypaque and Percoll gradients (18, 19) . Cells were suspended in RPMI medium (Mediatech, Inc., Herndon, VA) containing 20% fetal bovine serum (FBS) (HyClone Laboratories, Inc., Logan, UT) and seeded into six-well tissue culture plates (Flow Laboratories, Inc., McLean, VA). 1 h after seeding, the nonadhering cells were washed with PBS and adhering monocytes were incubated with either AGE-BSA, BSA, LPS (Difco Laboratories, Inc., Detroit, MI), human IFN-r (Amgen, Inc., Thousand Oaks, CA), human IL-1fI (Genzyme Corp., Boston, MA), human TNF (Chiron Corp., Emeryville, CA), or human PDGF from platelets (Collaborative Research, Inc., Bedford, MA). For specific experiments monocytes were incubated with AGE-BSA in the presence of 100 Mg/ml anti-IL-lB antibody, 100 Mg/ml anti-TNF antibody (both from Genzyme Corp.) or 50,g/iml anti-platelet PGDF antibody (Collaborative Research, Inc.). RNA was extracted by a modified guanidinium isothiocyanate method (RNAzol TM, Cinna/Biotecx, Friendswood, TX). In other experiments, monocytes were incubated for 30 min at 40C with 20 Mg/ml avian anti-60 kD or anti-90 kD anti-AGE receptor antibodies raised against the respective rat liver membrane AGE-binding proteins (8) . The cells were transferred to 370C and 150 Mg/ml AGE-BSA, and 20 Mg/ml anti-AGE receptor antibodies were added. For the ensuing 6 h more antibody was added hourly. The cultures were then washed and allowed to incubate in medium containing 20% FBS for 18 h, at which point total cellular RNA was extracted as described above.
Preparation of AGE-modified bovine serum albumin. AGE-BSA was prepared by incubating BSA (Fraction V, Boehringer Mannheim, Indianapolis, IN) in phosphate-buffered saline (PBS) (150 mM, pH 7.4) with 50 mM glucose-6-phosphate at 370C for 6 (20) . Control BSA was incubated under the same conditions without glucose-6-phosphate. Endotoxin content in each sample was measured by the Limulus amoebocyte lysate assay (E-Toxate, Sigma Chemical Co., St. Louis, MO) and found to be below detectable levels (< 0.2 ng/ml). AGE-specific fluorescence was determined at 450 nm upon excitation at 390 nm using an LS-3B fluorescence spectrometer (Perkin-Elmer Corp., Norwalk, CT) and by an AGE-specific radioreceptor assay (20a). AGE-BSA contained 45 AGE-U/mg protein and native BSA 0.3 AGE-U/mg protein.
Preparation offibronectin-coated tissue culture plates. Human fibronectin (Collaborative Research, Inc.) was incubated with 50 mM G-6-P at 37°C for 6 wk as described above for BSA, as were parallel preparations incubated in the absence of sugar, and then plated at 10 ,Mg/ml onto six-well tissue culture plates. The plates were allowed to dry overnight and gently washed three times with PBS, before freshly isolated monocytes were allowed to adhere. Attachment ofAGE-modified or native fibronectin to the tissue culture plates was monitored as described by Jones et al. (21) A Sepharose beads with 0.02% NaN3 were added to the supernatants to precipitate antibody and radiolabeled ligand and the solutions were incubated for 12 h at 4°C with continuous shaking. The protein A beads were washed three times each in the following buffers: 0.1% Triton X-100/0.02% SDS/50 mM Hepes; 1.0% Triton X-100/0.2% SDS, 50 mM Hepes; 0.1% Triton X-100/0.02% SDS/50 mM Hepes/0.4 M NaCI; and finally PBS. The beads were subsequently washed in SDS-PAGE sample buffer, boiled and the supernatants were run on a gradient SDS-polyacrylamide gel ( 10-18%) in the presence of/3-mercaptoethanol. Recombinant human IGF-I (receptor grade, Collaborative Research, Inc.) labeled with '25I, using the Bolton Hunter reagent kit (ICN Radiochemicals, Irvine, CA) was also immunoprecipitated from methionine-free RPMI + 20% dialyzed FCS using identical procedures as for the media, and was used as a radiolabeled marker in conjunction with a prestained low molecular ladder of standards (Bio-Rad Laboratories, South Richmond, CA). The resulting gel was processed with an autoradiograph enhancer (Enhance, DuPont-New England Nuclear, Boston, MA), dried, and autoradiographed. IGF-I assays. Immunoreactivity for the IGF-IA E peptide was determined from monocyte-conditioned media samples by radioimmunoassay (RIA), as described previously (28) . This RIA has been shown to be highly specific for the IGF-IA E peptide and not mature IGF-I or IGF-II. Levels of immunoreactive IGF-I were determined by a specific RIA using anti-IGF-I antiserum from the National Hormone and Pituitary Program.
Results
Preliminary experiments employing PCR showed that human monocytes can be stimulated by AGE-modified BSA to express mRNA for IGF-I. As shown in Fig. 1 , IGF-I transcripts were readily detected from monocytes that had been treated with 150 ,g/ml endotoxin-free AGE-BSA for 24 h. However, treatment of monocytes with an equal amount ofunmodified BSA, f-actin bp in the presence or absence of 50 U/ml(IFN-r) failed to do so, indicating that IGF-I expression was a specific response to AGE-modified BSA. IGF-I mRNA levels were greatly reduced in monocytes treated simultaneously with AGE-BSA and IFNy. In addition, LPS, a potent inducer of multiple monocyte gene expression, failed to induce IGF-I mRNA at a concentration of 1 ug/ml. The DNA product generated in these studies had a predicted length of 268 bp of the IGF-I amplification product. The primers were chosen for the exon sequence separated by the third intron of the IGF-I gene; therefore, the observed band could only have originated from spliced mRNA and not from genomic DNA.
To ensure that the DNA PCR product generated using IGF-I primers originated from IGF-I mRNA, the isolated fragment was digested with the restriction enzymes Bam HI and Dra I, both of which are specific six basepair cutters. After amplification, isolation and digestion of the full length fragment with the respective restriction enzymes, individual fragment sizes were assessed by gel electrophoresis, which yielded fragments precisely of the expected sizes (data not shown).
Characterization Fig. 3 , immobilized glycosylated fibronectin induced IGF-I mRNA expression in a similar fashion to soluble AGE-modified albumin, while nonglycosylated fibronectin did not. As observed earlier (Fig. 1) , in the presence of IFN-r (50 U/ml) less IGF-IA mRNA could be detected. Parallel expression off,-actin mRNA demonstrated comparable loading of reverse transcribed RNA in these studies (Fig. 3) .
It has been reported previously that AGE-BSA induces both IL-1# and TNF-a message and protein in human monocytes (3). To relate the time-dependent patterns of induction of IL-1, and TNF-a to that of IGF-I mRNA following exposure to AGE-proteins, monocyte induction ofall three mRNAs was studied at different time points after exposure to AGE-BSA. PCR analysis revealed that IL-,# and TNF-a mRNAs are expressed as early as 2 h after exposure to AGE-BSA (Fig. 4) . After treatment in the presence of anti-TNF-a antibody had no effect, suggesting that induction of IGF-I mRNA is partly mediated via AGE-induced IL-1#.
We have recently reported that AGE-stimulated monocytes also release PDGF (4). Because PDGF is a known mediator of IGF-I mRNA, monocytes were incubated with AGE-BSA in the presence of anti-platelet PDGF antibody. Under those conditions no IGF-I mRNA was produced, indicating that it may also be regulated via AGE-mediated PDGF secretion. To further substantiate these findings, human TNF-a, IL-1p, and PDGF were added to monocytes directly. As shown in Fig. 5 , the direct addition of either IL-1: or PDGF led to enhanced IGF-I mRNA expression, while TNF-a did not. This is consistent with the notion that the AGE-stimulated enhancement of IGF-I mRNA levels is mediated via either IL-I/3 or PDGF.
Recently an AGE-receptor system has been identified on macrophages and monocytes consisting of two binding proteins, one with an M, of 60 kD and the other of 90 kD, and neutralizing polyclonal antibodies have been subsequently developed (8) . To determine whether the induction of IGF-IA mRNA by AGE-modified proteins is mediated via this receptor system, monocytes were incubated with AGE-BSA in the presence ofeither anti-p60 or anti-p90 AGE-receptor antibodies. To allow time for antibody equilibration and maintain constant contact with the recycling AGE-receptors, the cells were pretreated with either antibody (20 ,g/ml) for 30 min at 4VC before and hourly afterwards. As indicated in Fig. 6 , only a trace amount of IGF-IA mRNA was detectable in monocytes treated simultaneously with AGE-BSA and the anti-p60 antibody or both anti-p60 and anti-p90 in combination, indicating inhibition of IGF-I induction above control levels. Antip90 antibody alone had a much smaller inhibitory effect on the IGF-I response (up to 37% ofcontrol as assessed by densitometric analysis).
Induction of mRNA in response to a stimulus is not always followed by the secretion of the corresponding protein. It was therefore important to determine whether AGE-BSA could in fact induce the secretion of IGF-I protein by human monocytes. Using a rabbit polyclonal anti-IGF-I antibody, the supernatants of monocytes treated for 24 h with AGE-BSA or with zymosan A (a yeast protein-carbohydrate complex, used as a positive control due to its ability to nonspecifically induce macrophages to produce IGF-I) were immunoprecipitated. An Supernatants were harvested and IGF-I was immunoprecipitated with a rabbit polyclonal anti-human IGF-I antibody as described in Methods and electrophoresed on a gradient SDS-PAGE ( 10-18%). lodinated recombinant liver IGF-I (7.6 kD) was used as a positive control (lane 1). Representative oftwo identical experiments.
autoradiograph of SDS-PAGE from these cell cultures showed the precipitation ofa single protein of 13-14 kD (Fig. 7 , lanes 2 and 4), which is several kilodaltons larger than the recombinant hepatocyte IGF-I (7.6 kD) (Fig. 7, lane 1) . Only background levels of IGF-I-like protein could be detected in supernatants of either untreated or native BSA-treated cells.
Recently, Conover et al. (28) have described the secretion by growth hormone-treated fibroblasts of an IGF-I prohormone with a molecular mass of 13-19 kD. The nucleotide sequence of the cDNA of this molecule has indicated that the IGF-IA prohormone is derived from a region which extends an additional 35 amino acids beyond the carboxyterminal end of the mature IGF-I molecule. This has been termed E peptide. Because the IGF-I-like molecule secreted by AGE-stimulated monocytes and the IGF-I prohormone secreted by fibroblasts appeared similar in size, we questioned whether the species of IGF-I secreted by monocytes corresponds to the IGF-IA prohormone. Supernatants derived from either unmodified BSAor AGE-BSA-stimulated monocytes were tested by RIA for immunoreactivity with an antiserum directed against a synthetic segment of the predicted E peptide region which is unique to the IGF-IA prohormone (28) , as well as with an antibody that recognizes both, the prohormone as well as the mature IGF-I peptide. As shown in Table I , both antibodies recognized severalfold greater amounts of IGF-I in the super- It has been shown that some IGF-I secreting cells also secrete IGF-I binding proteins (12) (13) (14) . To test whether human monocytes secrete their own binding proteins under these conditions, supernatants from BSA and AGE-BSA treated monocytes were assayed for IGF-I binding proteins by ligand blotting (29) . No binding proteins could be detected however (data not shown).
Discussion
Monocytes and macrophages play an important role in connective tissue homeostasis and normal remodeling. A recently proposed mechanism by which these cells can selectively identify, internalize, and remove senescent proteins operates via a monocyte/macrophage receptor system specific for the AGEmoieties that form on proteins as tissues are exposed to ambient glucose (30, 31 ). Receptor-mediated uptake ofAGE-proteins initiates a sequence of cytokine-mediated processes known to promote tissue remodeling (3) by recruiting cells of mesenchymal origin and initiating cellular proliferation, new matrix protein synthesis and/or release of extracellular proteases (5) . In addition, we have demonstrated that AGE-modified substrates induce monocytes to secrete PDGF (4), shown to act as a "competence" factor by priming cells of mesenchymal origin to enter mitosis. We therefore pursued our search for the terminal mediator responsible for cell proliferation and tissue remodeling which is induced by AGE-proteins via the AGE-receptor-cytokine-growth factor cascade.
IGF-I, among the known growth promoting peptides and according to the "dual control" concept of cell proliferation, is one of the "progression" factors which prompt "competence" factor-primed fibroblasts to proceed through GI phase (9) . In this context, we inquired whether IGF-I is involved in the AGE-mediated tissue remodeling network of responses likely to participate in normal tissue remodeling. An AGE-protein specific increase in IGF-I mRNA was observed in human monocytes. Induction of IGF-IA mRNA was AGE dose-dependent, and was equally well elicited in response to soluble AGE-BSA as it was to insoluble AGE-fibronectin. This is of particular significance in vivo, because most structural tissue components, e.g., collagen and basement membrane proteins, by virtue of their low physiologic turnover rates tend to accumulate AGEs (5, 6) .
Recently two AGE-specific receptor proteins were purified from rat liver membranes (p60 and p90) against each ofwhich 444 specific polyclonal antibodies were raised (8) . By using these antibodies, it was established that the induction of IGF-IA mRNA by glucose-modified proteins is mediated specifically via the AGE-receptor system. No IGF-IA mRNA induction was observed in the presence ofanti-p60 antibody, whereas the anti-p90 antibody only inhibited the response partially. This is consistent with the previously expressed notion that, ofthe two receptor subunits, the p60 may be the one more capable of immobilizing AGE-ligands by itself as compared to the p90 (8) . Although the subsequent events following the receptor-ligand coupling need be further elucidated, the present data point to the AGE-receptor system present at the cell surface as the primary initiator ofa complex process that leads eventually to IGF-I secretion.
The time-dependent course of IGF-IA mRNA increase revealed strong expression after 48 h of exposure to AGEs, a pattern distinctly different from that observed for the AGEtriggered increases in IL-lI# and TNF-a mRNA. Both of these messages appeared earlier (after 2 h) and disappeared within 12 h of cell exposure to AGE-BSA ligand. This difference in latency caused us to speculate that IGF-I mRNA expression might occur indirectly, mediated by either IL-1: or TNF-a. The presence ofanti-IL-If antibody prevented the AGE-stimulated increase in IGF-I mRNA levels, while anti-TNF-a antibody did not, suggesting that IL-lI# may act as an intermediary factor in this system. Consistent with this, adding IL-I( alone to the cells reproduced the increase in IGF-I mRNA.
Alternative pathways however seem to exist, especially inasmuch as IGF-I is inducible in other cells, such as fibroblasts or human thyroid follicular cells by growth hormone (GH) and thyroid stimulating hormone (TSH) (28, 32) . Addition ofGH to monocytes failed to elicit an increase in IGF-IA mRNA (data not shown); however, the addition of platelet-derived growth factor (PDGF) promptly elicited a significant response. This novel observation may be of particular interest given the fact that AGE-modified proteins can stimulate human monocytes to secrete PDGF (4), a factor widely implicated in the mesenchymal proliferative responses typical of atherosclerosis (33, 34 
